- Home
- WFC vs AZN Comparison
WFC vs AZN Comparison
Compare WFC & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFC
- AZN
- Stock Information
- Founded
- WFC 1852
- AZN 1992
- Country
- WFC United States
- AZN United Kingdom
- Employees
- WFC N/A
- AZN N/A
- Industry
- WFC Major Banks
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- WFC Finance
- AZN Health Care
- Exchange
- WFC Nasdaq
- AZN Nasdaq
- Market Cap
- WFC 249.8B
- AZN 225.1B
- IPO Year
- WFC N/A
- AZN 1993
- Fundamental
- Price
- WFC $62.07
- AZN $62.21
- Analyst Decision
- WFC Buy
- AZN Strong Buy
- Analyst Count
- WFC 19
- AZN 7
- Target Price
- WFC $75.53
- AZN $89.75
- AVG Volume (30 Days)
- WFC 18.2M
- AZN 6.3M
- Earning Date
- WFC 04-11-2025
- AZN 04-29-2025
- Dividend Yield
- WFC 2.41%
- AZN 2.31%
- EPS Growth
- WFC 11.18
- AZN 18.11
- EPS
- WFC 5.37
- AZN 4.50
- Revenue
- WFC $77,962,000,000.00
- AZN $54,073,000,000.00
- Revenue This Year
- WFC $9.92
- AZN $8.64
- Revenue Next Year
- WFC $4.52
- AZN $6.11
- P/E Ratio
- WFC $12.36
- AZN $14.84
- Revenue Growth
- WFC 0.99
- AZN 18.04
- 52 Week Low
- WFC $50.15
- AZN $61.24
- 52 Week High
- WFC $81.50
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- WFC 29.06
- AZN 20.90
- Support Level
- WFC $58.42
- AZN $63.93
- Resistance Level
- WFC $72.47
- AZN $75.70
- Average True Range (ATR)
- WFC 2.54
- AZN 1.67
- MACD
- WFC -1.03
- AZN -1.34
- Stochastic Oscillator
- WFC 21.52
- AZN 5.05
About WFC Wells Fargo & Company
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.